Journal of Nuclear Medicine最新文献

{"title":"C-X-C Motif Chemokine Receptor 4-Directed Scintigraphy of Multiple Myeloma Using [^99mTc]Tc-PentixaTec.","authors":"Johanna S Enke, Nic G Reitsam, Bianca Grosser, Malte Kircher, Alexander Dierks, Ralph A Bundschuh, Georgine Wienand, Luise Uhrmacher, Martin Trepel, Margret Schottelius, Constantin Lapa, Christian H Pfob","doi":"10.2967/jnumed.123.266305","DOIUrl":"10.2967/jnumed.123.266305","url":null,"abstract":"","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2024-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10246111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Debating the Future of Nuclear Medicine: The Greek Experience.","authors":"Panagiotis Georgoulias, George Angelidis, Sophia Koukouraki, John Koutsikos","doi":"10.2967/jnumed.123.266646","DOIUrl":"10.2967/jnumed.123.266646","url":null,"abstract":"","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2024-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10246112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of68Ga-FAPI-04 and18F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer","authors":"Ying Miao, Runhua Feng, Teng Yu, R. Guo, Min Zhang, Yue Wang, W. Hai, C. Shangguan, Zhenggang Zhu, Biao Li","doi":"10.2967/jnumed.123.266403","DOIUrl":"https://doi.org/10.2967/jnumed.123.266403","url":null,"abstract":"","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138951752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of (R)-[18F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development","authors":"Yingfang He, Stefanie D. Krämer, U. Grether, Matthias B. Wittwer, Ludovic Collin, Bernd Kuhn, Andreas Topp, Dominik Heer, Fionn O’Hara, Michael Honer, Anto Pavlović, Hans Richter, Martin Ritter, Didier Rombach, C. Keller, L. Gobbi, Linjing Mu","doi":"10.2967/jnumed.123.266426","DOIUrl":"https://doi.org/10.2967/jnumed.123.266426","url":null,"abstract":"","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138950865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis","authors":"Liene Friebe, Martin T. Freitag, Martin Braun, Guillaume P. Nicolas, Andreas Bauman, David Bushnell, Emanuel Christ, Damian Wild","doi":"10.2967/jnumed.123.265894","DOIUrl":"https://doi.org/10.2967/jnumed.123.265894","url":null,"abstract":"","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138948816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with ⁸⁹Zr or ²¹¹At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma.","authors":"Tadashi Watabe, Kazuya Kabayama, Sadahiro Naka, Ryuku Yamamoto, Kazuko Kaneda, Satoshi Serada, Kazuhiro Ooe, Atsushi Toyoshima, Yang Wang, Hiromitsu Haba, Kenta Kurimoto, Takanori Kobayashi, Eku Shimosegawa, Noriyuki Tomiyama, Koichi Fukase, Tetsuji Naka","doi":"10.2967/jnumed.123.266313","DOIUrl":"10.2967/jnumed.123.266313","url":null,"abstract":"<p><p>Glypican-1 (GPC1) is overexpressed in several solid cancers and is associated with tumor progression, whereas its expression is low in normal tissues. This study aimed to evaluate the potential of an anti-GPC1 monoclonal antibody (GPC1 mAb) labeled with ⁸⁹Zr or ²¹¹At as a theranostic target in pancreatic ductal adenocarcinoma. <b>Methods:</b> GPC1 mAb clone 01a033 was labeled with ⁸⁹Zr or ²¹¹At with a deferoxamine or decaborane linker, respectively. The internalization ability of GPC1 mAb was evaluated by fluorescence conjugation using a confocal microscope. PANC-1 xenograft mice (<i>n</i> = 6) were intravenously administered [⁸⁹Zr]GPC1 mAb (0.91 ± 0.10 MBq), and PET/CT scanning was performed for 7 d. Uptake specificity was confirmed through a comparative study using GPC1-positive (BxPC-3) and GPC1-negative (BxPC-3 GPC1-knockout) xenografts (each <i>n</i> = 3) and a blocking study. DNA double-strand breaks were evaluated using the γH2AX antibody. The antitumor effect was evaluated by administering [²¹¹At]GPC1 mAb (∼100 kBq) to PANC-1 xenograft mice (<i>n</i> = 10). <b>Results:</b> GPC1 mAb clone 01a033 showed increased internalization ratios over time. One day after administration, a high accumulation of [⁸⁹Zr]GPC1 mAb was observed in the PANC-1 xenograft (SUV_max, 3.85 ± 0.10), which gradually decreased until day 7 (SUV_max, 2.16 ± 0.30). The uptake in the BxPC-3 xenograft was significantly higher than in the BxPC-3 GPC1-knockout xenograft (SUV_max, 4.66 ± 0.40 and 2.36 ± 0.36, respectively; <i>P</i> = 0.05). The uptake was significantly inhibited in the blocking group compared with the nonblocking group (percentage injected dose per gram, 7.3 ± 1.3 and 12.4 ± 3.0, respectively; <i>P</i> = 0.05). DNA double-strand breaks were observed by adding 150 kBq of [²¹¹At]GPC1 and were significantly suppressed by the internalization inhibitor (dynasore), suggesting a substantial contribution of the internalization ability to the antitumor effect. Tumor growth suppression was observed in PANC-1 mice after the administration of [²¹¹At]GPC1 mAb. Internalization inhibitors (prochlorperazine) significantly inhibited the therapeutic effect of [²¹¹At]GPC1 mAb, suggesting an essential role in targeted α-therapy. <b>Conclusion:</b> [⁸⁹Zr]GPC1 mAb PET showed high tumoral uptake in the early phase after administration, and targeted α-therapy using [²¹¹At]GPC1 mAb showed tumor growth suppression. GPC1 is a promising target for future applications for the precise diagnosis of pancreatic ductal adenocarcinoma and GPC1-targeted theranostics.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41203746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Somatostatin Receptor Antagonists as a Theranostic Option in Iodine-Refractory Thyroid Carcinoma.","authors":"Johanna S Enke, Ralph A Bundschuh, Georgine Wienand, Nic G Reitsam, Malte Kircher, Christian H Pfob, Constantin Lapa, Alexander Dierks","doi":"10.2967/jnumed.123.265639","DOIUrl":"10.2967/jnumed.123.265639","url":null,"abstract":"","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9995546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sequential and Combination Therapies of ²²³RaCl₂ and Prostate-Specific Membrane Antigen Radioligand Therapy.","authors":"Hossein Jadvar","doi":"10.2967/jnumed.123.266427","DOIUrl":"10.2967/jnumed.123.266427","url":null,"abstract":"","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41203807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ChatGPT: Can You Prepare My Patients for [¹⁸F]FDG PET/CT and Explain My Reports?","authors":"Julian M M Rogasch, Giulia Metzger, Martina Preisler, Markus Galler, Felix Thiele, Winfried Brenner, Felix Feldhaus, Christoph Wetz, Holger Amthauer, Christian Furth, Imke Schatka","doi":"10.2967/jnumed.123.266114","DOIUrl":"10.2967/jnumed.123.266114","url":null,"abstract":"<p><p>We evaluated whether the artificial intelligence chatbot ChatGPT can adequately answer patient questions related to [¹⁸F]FDG PET/CT in common clinical indications before and after scanning. <b>Methods:</b> Thirteen questions regarding [¹⁸F]FDG PET/CT were submitted to ChatGPT. ChatGPT was also asked to explain 6 PET/CT reports (lung cancer, Hodgkin lymphoma) and answer 6 follow-up questions (e.g., on tumor stage or recommended treatment). To be rated \"useful\" or \"appropriate,\" a response had to be adequate by the standards of the nuclear medicine staff. Inconsistency was assessed by regenerating responses. <b>Results:</b> Responses were rated \"appropriate\" for 92% of 25 tasks and \"useful\" for 96%. Considerable inconsistencies were found between regenerated responses for 16% of tasks. Responses to 83% of sensitive questions (e.g., staging/treatment options) were rated \"empathetic.\" <b>Conclusion:</b> ChatGPT might adequately substitute for advice given to patients by nuclear medicine staff in the investigated settings. Improving the consistency of ChatGPT would further increase reliability.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10241207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior ²²³Ra (RALU Study).","authors":"Kambiz Rahbar, Markus Essler, Matthias Eiber, Christian la Fougère, Vikas Prasad, Wolfgang P Fendler, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A Bundschuh, Kim M Pabst, Milena Kurtinecz, Anja Schmall, Frank Verholen, Oliver Sartor","doi":"10.2967/jnumed.123.266125","DOIUrl":"10.2967/jnumed.123.266125","url":null,"abstract":"<p><p>²²³Ra-dichloride (²²³Ra) and ¹⁷⁷Lu-prostate-specific membrane antigen (PSMA) are approved treatments for metastatic castration-resistant prostate cancer (mCRPC). The safety and effectiveness of sequential use of ²²³Ra and ¹⁷⁷Lu-PSMA in patients with mCRPC are not well described. This study aimed to evaluate ¹⁷⁷Lu-PSMA safety and efficacy in patients with mCRPC previously treated with ²²³Ra. <b>Methods:</b> The radium→lutetium (RALU) study was a multicenter, retrospective, medical chart review. Participants had received at least 1 ²²³Ra dose and, in any subsequent therapy line, at least 1 ¹⁷⁷Lu-PSMA dose. Primary endpoints included the incidence of adverse events (AEs), serious AEs, grade 3-4 hematologic AEs, and abnormal laboratory values. Secondary endpoints included overall survival, time to next treatment/death, and change from baseline in serum prostate-specific antigen and alkaline phosphatase levels. <b>Results:</b> Data were from 133 patients. Before ¹⁷⁷Lu-PSMA therapy, 56% (75/133) of patients received at least 4 life-prolonging therapies; all patients received ²²³Ra (73% received 5-6 injections). Overall, 27% (36/133) of patients received at least 5 ¹⁷⁷Lu-PSMA infusions. Any-grade treatment-emergent AEs were reported in 79% (105/133) of patients and serious AEs in 30% (40/133). The most frequent grade 3-4 laboratory abnormalities were anemia (30%, 40/133) and thrombocytopenia (13%, 17/133). Median overall survival was 13.2 mo (95% CI, 10.5-15.6 mo) from the start of ¹⁷⁷Lu-PSMA. <b>Conclusion:</b> In this real-world setting, ²²³Ra followed by ¹⁷⁷Lu-PSMA therapy in heavily pretreated patients with mCRPC was clinically feasible, with no indication of impairment of ¹⁷⁷Lu-PSMA safety or effectiveness.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41203743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}